Benoholdings, Inc. Overview
AinsFac CNS is a loss-making KOSDAQ micro-cap holding company with a history of repeated reinvention. It began in 2001 as Entermate, an internet-service and online/mobile game publisher focused on Chinese-language titles. In 2020 it became Benoholdings and pivoted toward biotech by taking control of Beno Bio. In 2023 it became BENO TNR, adding:
-
an interior-construction business (exterior shading systems, eco double-floor systems, radiant heating and cooling panels);
-
a controlling stake in Canadian wearable-exoskeleton developer Human in Motion Robotics (product: XoMotion).
In 2026 it bought a duct-manufacturing business. It then changed control to a new technology investment fund and was renamed AinsFac CNS. Its articles now list semiconductor, display, solar and battery equipment, smart-factory automation, recycling and energy-storage businesses, none of which yet generates disclosed revenue.
Operating revenue is small: about KRW 3.6bn over the trailing twelve months to June 2026. The equity value sits largely in investments and intangibles. The investment case is therefore driven less by current operations than by:
-
the new owner's capital injection;
-
the company's ability to stay listed under Korea's tightened 2026 delisting rules;
-
whether the robotics and bio affiliates ever produce revenue.
What the company does today
The H1 2026 interim report, as summarised by Bloter (15 Sep 2026), describes the company's main business as interior construction and duct manufacturing:
-
H1 2026 revenue was about KRW 1.4bn.
-
Duct manufacturing contributed about KRW 0.7bn, roughly half of the total.
-
The duct business was acquired in 2026 from 금영이엔씨 (Geumyoung E&C) for about KRW 0.8bn.
Butler.works, which aggregates DART data, gives a Q2 2026 revenue mix of Construction 54% / Duct manufacturing 46%.
Korean Wikipedia and Bullstory describe the operating scope as follows:
Interior construction: development, design, manufacture and installation of building shading systems (차양시스템), eco-friendly double/raised flooring (친환경 이중바닥재) and radiant heating/cooling systems (복사냉난방시스템).
Wearable robotics: through Human in Motion Robotics Inc. (Canada) and Human in Motion Robotics Asia (Korea JV). The flagship is the lower-limb, self-balancing exoskeleton XoMotion; XoMotion-R is the rehabilitation model.
Bio: through Beno Bio (베노바이오), an affiliate doing drug discovery. Its disclosed work includes an epigenetics-based drug programme, an injectable composition for a next-generation macular-degeneration therapy (patent registered mid-2026) and a Pan-KRAS programme.
Duct manufacturing: acquired 2026.
New objects added to the articles at the 29 Sep 2026 EGM: - Equipment for semiconductors, LCD, OLED, solar and secondary batteries.
-
Ultrapure-water and water-purification plant.
-
Smart-factory logistics automation.
-
Recycling of waste batteries and waste solar panels.
-
Energy storage systems (ESS) and EV charging. No investment amounts or commercialisation timelines have been disclosed for these (Bloter; Money Today via Nate).
Business and revenue model
| Revenue model element | Status | Comment |
|---|---|---|
| Project/contract revenue (interior construction) | Active | Project-based, lumpy. A "single sales/supply contract" was disclosed on 30 Jul 2026 (Butler.works filing list); its value is not disclosed in reviewed sources. |
| Product manufacturing revenue (ducts) | Active from 2026 | About KRW 0.7bn in H1 2026 (Bloter) |
| Product sales (exoskeletons) | Pre-commercial in Korea | Human in Motion Robotics Asia had no revenue in H1 2026 and a net loss of about KRW 0.5bn (Bloter). XoMotion-R received Health Canada approval and a first sales contract was reported in Jan 2025 (Asia Economy). |
| Licensing / technology export (bio) | No disclosed revenue | Beno Bio's stated route is clinical development, technology export and co-research (Asia Economy, Nov 2020). |
| Game publishing (legacy Entermate) | Status not publicly disclosed | In 2020 the CEO said the game publishing business was expected to remain operating-profitable. No current game revenue is visible in 2026 segment data. |
| Subscription | — | — |
Value-chain position, customers and end markets
| Business | Value-chain position | Customer types | End market |
|---|---|---|---|
| Interior construction | Design-manufacture-install specialist subcontractor | Building owners, general contractors (named customers not publicly disclosed) | Korean commercial and residential building fit-out |
| Duct manufacturing | Component manufacturer | Construction and HVAC contractors (not publicly disclosed) | Building HVAC |
| Wearable robotics | Device OEM (design, development, regulatory approval) with distribution partners | Rehabilitation hospitals and clinics; distributors such as Robotimize (Singapore) | Rehabilitation and assistive medical devices |
| Bio | Early-stage drug discovery | Prospective licensees and pharma partners | Ophthalmology (macular degeneration), oncology (KRAS) |
Company self-description vs. independent characterisation
Company's own description: (per its trade-name and EGM filings): the purpose of the 2026 rename and objects expansion is "achieving management objectives and business diversification" (paraphrased from the DART change-of-trade-name filing reported by Digital Today).
Independent characterisation: a capital-markets vehicle whose operating businesses are sub-scale. Three points support this:
-
Revenue trend. Revenue fell from KRW 25.3bn (FY2024) to KRW 4.77bn (FY2025) and is about KRW 3.6bn TTM (Butler.works; Valueline).
-
Losses. Operating losses have occurred every year since FY2022.
-
Financing-heavy history. Strategy has repeatedly been carried by control transactions, renames and financing rather than organic growth. Recent examples:
-
2023: control change and rename to BENO TNR.
-
2025: a KRW 30bn financing plan with Haemil IB.
-
2026: control sale at a roughly 600% premium, a rename, a 10x increase in authorised share capital and a 50x increase in convertible-bond capacity.
-
Strategy
Stated strategy themes
Benoholdings era (2020):
-
Keep game publishing operating-profitable.
-
Launch new games in 2021.
-
Expand through new-drug R&D centred on Beno Bio.
Source: CEO Jeong Jip-hun, Asia Economy (Nov 2020).
BENO TNR era (2023–2026):
-
Become a global wearable-robot company. Management cited growth above 42% per year for the global wearable-robot market (a company-cited figure).
-
Add AI software capability through the 2024 Alticast investment.
-
Expand toward AI humanoid robotics.
-
Take Human in Motion Robotics public on KOSDAQ via a technology-special listing (IPO mandate Oct 2025).
Sources: eToday; Asia Economy.
AinsFac CNS era (Sep 2026–):
-
Business diversification into semiconductor, display, solar and battery equipment, ultrapure water, smart-factory automation, battery and solar recycling, ESS and EV charging.
-
Substantial increase in financing capacity.
-
No targets, capex plans or timelines disclosed.
Source: Bloter; Money Today via Nate.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Alticast investment | Dec 2024 | Rights issue plus perpetual CB investment, aimed at robot software and AI synergies | Completed Dec 2024. Outcome and value not publicly disclosed. |
| XoMotion-R commercialisation | Jan 2025 | Health Canada approval; first sales contract | Revenue contribution not publicly disclosed |
| ASEAN distribution (Robotimize) | Mar 2025 | Sales and strategic partnership | No revenue disclosed; HMR Asia had zero revenue in H1 2026 |
| Haemil IB KRW 30bn financing | Jul 2025 | KRW 10bn CB plus KRW 20bn rights issue | — |
| HMR KOSDAQ IPO preparation | Oct 2025 | Eugene Investment & Securities appointed as lead manager | Pending |
| K-Humanoid Alliance participation (HMR Asia) | 2,025 | Selected as a participating company | Ongoing |
| Duct manufacturing acquisition | 2,026 | Geumyoung E&C duct business, about KRW 0.8bn | Completed; about 46% of Q2 2026 revenue |
| Control change and recapitalisation | Jul–Dec 2026 | KRW 33.96bn share purchase plus KRW 10bn placement | Share purchase closed 28 Sep; placement due 23 Dec 2026 |
| Delisting-risk remediation | Sep–Oct 2026 | 2:1 consolidation (scheduled 16 Oct) and 5:1 capital reduction (scheduled 29 Oct). The stated purpose of the reduction was changed in a 14 Sep correction from deficit offset to capital efficiency and share-price stabilisation. | Scheduled |
| Articles amendment | 29 Sep 2026 | Authorised shares 500m → 5bn. CB and BW limits KRW 300bn → KRW 5tn each. EB limit KRW 100bn → KRW 5tn. | EGM agenda per Bloter |
Medium-term targets and guidance
None publicly disclosed. The 2015 target of KRW 100bn+ revenue by 2020 was not achieved: peak disclosed revenue in FY2021–FY2025 was KRW 26.7bn.
ESG / sustainability commitments
None publicly disclosed.
Products & Services
Interior construction
| Product / service | Description | Target customer | Launch year | Pricing | Source |
|---|---|---|---|---|---|
| Shading systems (차양시스템) | Development, design, manufacture and installation of building shading systems | Commercial and residential building projects | — | Project-based; not publicly disclosed | Korean Wikipedia; Bullstory |
| Eco-friendly double/raised floor (친환경 이중바닥재) | Raised-floor systems: design and installation | Office and commercial fit-out | — | Project-based | Korean Wikipedia |
| Radiant heating/cooling systems (복사냉난방시스템) | Radiant panel heating and cooling: development, design, installation | Building owners and contractors | — | Project-based | Korean Wikipedia; Bullstory |
Duct manufacturing
| Product | Description | Source |
|---|---|---|
| Ducts | Manufactured ducts (business acquired from Geumyoung E&C in 2026 for about KRW 0.8bn). About KRW 0.7bn of H1 2026 revenue. Product specifications not publicly disclosed. | Bloter |
Wearable robotics (Human in Motion Robotics / HMR Asia)
| Product | Description and capabilities | Target customer | Status / version | Source |
|---|---|---|---|---|
| XoMotion | Lower-limb bipedal exoskeleton with self-balancing that lets users with paraplegia walk without crutches ("hands-free"). Has 12 actuators and intelligent software for natural gait, and was demonstrated climbing stairs. The company claims a torque-to-weight ratio 2.9x that of Tesla's Optimus (company claim). | People with lower-limb paralysis; rehabilitation centres | Unveiled in Korea 26 Oct 2023 | Asia Economy (Dec 2023); eToday (Oct 2023) |
| XoMotion-R | Rehabilitation-therapy version | Rehabilitation hospitals and clinics | Health Canada approval and first sales contract (reported Jan 2025). US FDA and Korean MFDS approvals were in progress as of Oct 2025. | Asia Economy (Jan 2025; Oct 2025) |
| Personal-use model | Model for daily use by people with gait impairment, with enhanced AI | Individual users | Under development (Oct 2025) | Asia Economy (Oct 2025) |
| AI humanoid robotics (aspirational) | Stated ambition to extend from wearables to AI-based humanoid robots. Discussions on AI and robotics R&D with Nvidia were described by the company. | — | Concept stage; no product disclosed | Asia Economy (Oct 2025) |
Bio (Beno Bio)
| Programme | Description | Stage | Source |
|---|---|---|---|
| Next-generation macular-degeneration injection composition | Injectable formulation; patent registered | Patent registered (reported June 2026); clinical stage not publicly disclosed | StockHub headline citing Asia Economy (Jun 2026) |
| Pan-KRAS programme | Oncology candidate selected for the "2026 Global Company Collaboration Program" | Preclinical/early (not publicly disclosed) | Asia Economy related-article listing (2026) |
| Epigenetics-based drug candidates | Drug research using epigenetics | Research stage | Bullstory company profile |
Legacy game publishing (Entermate)
| Title | Format | Year | Current status |
|---|---|---|---|
| Shinsundo (신선도) | Web game (Chinese localisation) | 2,012 | — |
| Waryong Jeonseol (와룡전설), Amheuk Samguk (암흑삼국), Cheonnyeondo (천년도) | Web games | 2012–2015 | — |
| I Love Three Kingdoms for Kakao; Be My Slave for Kakao; 1-Minute RPG for Kakao | Mobile (Kakao) | 2013– | — |
| Arcane (아케인) | Mobile RPG | Oct 2015 | — |
Source for this table: iNews24 (Oct 2015). In 2015 the company said it operated about 20 games in Korea, eight of which earned more than KRW 1bn each in 2014.
New business objects (added to the articles, Sept 2026, no products yet)
| Object | Status |
|---|---|
| Semiconductor, LCD, OLED, solar and secondary-battery equipment | Articles only; no products, investment or timeline disclosed |
| Ultrapure-water and water-purification plant; water treatment | Articles only |
| Smart-factory logistics automation | Articles only |
| Waste-battery and waste-solar-panel recycling | Articles only |
| ESS; EV charging | Articles only |
Sources for this table: Bloter; Money Today via Nate (15 Sep 2026).
Financial Narrative
Basis. Consolidated, K-IFRS. Annual figures FY2021–FY2024 are from Butler.works (DART-derived, rounded to KRW 0.1bn). FY2025 figures are from the annual-report values in Korean Wikipedia's infobox (KRW 4,774,718,589 / −5,361,474,305 / −24,026,574,843), which agree with Butler.works. Readers should reconcile against the DART business reports before relying on them.
Interim and trailing data: notes and sources
Source: Dealsite (20 Aug 2026), citing the H1 2026 report. Revenue fell 44% YoY and the operating loss widened 74%.
Source: Valueline trailing-twelve-month series (displayed in 억원). This is consistent with FY2025 KRW 4.77bn − H1 2025 KRW 2.57bn + H1 2026 KRW 1.44bn = KRW 3.64bn.
Balance sheet
Equity-decline note. Equity fell KRW 6.3bn in six months. That is roughly 2.2x the H1 operating loss, which implies further non-operating losses, valuation changes or other comprehensive-income charges in H1 2026. The breakdown is not publicly disclosed in reviewed sources.
Cash flow
Known external financing events:
-
Dec 2024: investment into Alticast (cash outflow; amount not publicly disclosed).
-
Dec 2026 (scheduled): KRW 10bn placement to Acro Fund No.241 for working capital.
Commentary on trends, inflections and drivers
Structural revenue collapse with one anomalous year: Revenue shrank from KRW 26.7bn (FY2021) to KRW 9.9bn (FY2023), spiked to KRW 25.3bn in FY2024, then fell 81% to KRW 4.77bn in FY2025. Reviewed sources do not explain the FY2024 spike and FY2025 collapse. The pattern is consistent with either one or more large, non-recurring construction projects or a change in what was consolidated; the cause should be checked in the FY2024 and FY2025 business reports. The trailing series (KRW 11.2bn → 3.6bn over four quarters) shows the decline is still under way.
Persistent operating losses: The company has lost money at the operating level for four straight years, with KRW 24.0bn of cumulative operating losses over FY2022–FY2025. The FY2025 loss of KRW 5.36bn narrowed by about 45% in absolute terms but was larger than revenue (operating margin −112%). H1 2026 deteriorated again, with the loss widening 74% YoY on 44% lower revenue. Dealsite attributes this to falling sales combined with SG&A burden.
Below-the-line losses dominate: In FY2022 the net loss (KRW −21.9bn) was more than ten times the operating loss. In FY2025 the KRW −24.0bn net loss exceeded the KRW −5.4bn operating loss by about KRW 18.7bn. This is consistent with valuation or impairment losses on the investment portfolio (Beno Bio, Human in Motion Robotics, Alticast), but the components are not publicly disclosed in reviewed sources and are not presented here as fact.
FY2021 profit was non-operating: The FY2021 net profit (KRW 8.6bn) was well above operating profit (KRW 1.5bn), again pointing to non-operating gains whose nature is not publicly disclosed.
- Equity cushion is eroding but still substantial relative to market value. Equity of KRW 65.6bn against a market cap of about KRW 23bn means the market applies a deep discount (P/B about 0.35x) to the carrying value of the investment-heavy balance sheet.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Stake | Activity | Source |
|---|---|---|---|---|
AinsFac CNS Co., Ltd. | Listed parent | — | Interior construction, duct manufacturing, holding of investments | DART / Bloter |
Human in Motion Robotics Inc. (Canada) | Affiliate/subsidiary | 45.1% at entry (May 2023); described as largest shareholder. Current stake not publicly disclosed. | Wearable exoskeleton developer (XoMotion) | News Tomato (2023) |
Human in Motion Robotics Asia (Korea) | Subsidiary (JV) | 60% | Development, APAC sales, intended global production base | eToday (2023); Bloter (2026) |
Beno Bio (베노바이오) | Affiliate | 33% at Nov 2020. Current stake not publicly disclosed. | Drug discovery | Asia Economy (2020) |
Alticast Corp. (KOSDAQ 085810) | Investee | Rights issue plus perpetual CB investment (Dec 2024). Current stake and accounting treatment not publicly disclosed. | Software (Alticast's own 2026 portfolio includes 대현기건 and 압타머사이언스) | Asia Economy (Dec 2024; Apr 2026) |
Duct manufacturing business (ex-Geumyoung E&C) | Acquired business (asset deal) | 100% of business | Duct manufacturing | Bloter (2026) |
Segment Revenue
| Segment | Contents | H1 2026 revenue (KRW Bn) | Share of revenue (Q2 2026 basis) | Source |
|---|---|---|---|---|
Construction (interior) | Shading systems, double-floor systems, radiant heating and cooling | About 0.7 (by difference) | 54% | Bloter; Butler.works |
Duct manufacturing | Ducts (acquired 2026) | About 0.7 | 46% | Bloter; Butler.works |
Robotics | Human in Motion Robotics Asia (consolidated, 60%) | 0.0 | 0% | Bloter |
Bio | Beno Bio (equity-accounted or investment; treatment not publicly disclosed) | — | — | — |
Total (consolidated) | — | 1.44 | 100% | Dealsite (H1 revenue KRW 1,435.17m) |
Segment metric | Status | — | — | — |
Segment redefinitions or restatements | Duct manufacturing is a new segment in 2026. Earlier restatements are not publicly disclosed. | — | — | — |
“—” = not publicly disclosed.
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 26.7 | 21.8 | 9.9 | 25.3 | 4.77 |
Operating income (KRW Bn) | 1.5 | -1.9 | -7.0 | -9.7 | -5.36 |
Net income (KRW Bn) | 8.6 | -21.9 | -7.9 | -3.6 | -24.03 |
Revenue growth YoY (%) | — | -18.4 | -54.6 | 155.6 | -81.1 |
Operating margin (%) | 5.6 | -8.7 | -70.7 | -38.3 | -112.3 |
Net margin (%) | 32.2 | -100.5 | -79.8 | -14.2 | -503.2 |
Metric | Value | Basis | — | — | — |
Revenue CAGR FY2021–FY2025 | about −34.9% per year | Computed from the table above | — | — | — |
Gross profit | — | Not found in reviewed sources | — | — | — |
EBITDA | — | Not found in reviewed sources | — | — | — |
Pre-tax income | — | Not found in reviewed sources | — | — | — |
EPS (basic/diluted) by year | — | TTM EPS of −₩311 per Investing.com (Aug–Sep 2026) | — | — | — |
Dividends per share | 0 in all years | StockHub dividend yield 0.00%; no dividend found | — | — | — |
“—” = not publicly disclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Revenue (KRW Bn) | 2.57 | 1.44 |
Operating income (KRW Bn) | -1.62 | -2.82 |
Income Statement (Quarterly)
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
TTM revenue (KRW Bn) | 11.22 | 6.74 | 4.77 | 4.30 | 3.64 |
Balance Sheet
| Item | 31 Dec 2025 | 30 Jun 2026 | Source |
|---|---|---|---|
Total equity (KRW Bn) | 71.9 | 65.6 | Bloter (H1 2026 report) |
Share capital (KRW Bn) | About 18.8 | About 18.8 (falls to about 3.8 after capital reduction) | Money Today via Nate; Bloter |
Financial Analysis
| Item | FY2021–FY2025 |
|---|---|
Dividends paid | 0 (no dividends found) |
Buybacks | None found; treasury share ratio 0.00% (Butler.works) |
Financial Analysis — ROE
| Ratio | Value | Basis / source |
|---|---|---|
ROE (TTM) | −22.4% | Valueline (Sep 2026) |
ROE (TTM, alternative) | −24.43% | StockHub (Jul 2026) |
ROE (FY2025, on year-end equity) | about −33.4% | Computed: −24.03 / 71.9 |
P/B | 0.37x | Valueline (22 Sep 2026, ₩678) |
P/B (computed) | about 0.35x | KRW 23.2bn market cap / KRW 65.6bn equity, 12 Oct 2026 |
P/E | Not meaningful (losses); Valueline shows −1.67x | Valueline |
Price/Sales (TTM) | about 6.4x | Computed: KRW 23.2bn / KRW 3.64bn TTM revenue |
Geographic Revenue
| Item | Disclosure |
|---|---|
Geographic split (Korea vs. overseas), 3 years | Not publicly disclosed in a comparable series. Valueline's breakdown shows a domestic line (in 억원) and an export line marked N/A, which suggests revenue is overwhelmingly domestic. |
Overseas activity | Canada: Human in Motion Robotics (development; first XoMotion-R sales, 2025). ASEAN: distribution partnership with Robotimize (Singapore; targeting Singapore, Malaysia, Indonesia). Historical (2014–2015): Taiwan subsidiary and a Hong Kong JV for games. |
Fastest-growing region | Cannot be determined. Overseas robotics sales exist but are not quantified. |
Declining region | Domestic (Korea) construction revenue is the main source of the FY2025–H1 2026 decline. |
Share Price History
| Date | Close / price | Note | Source |
|---|---|---|---|
29 May 2025 | 1,820 | Market cap KRW 70.7bn; 1-year −44.6% | Simply Wall St |
6 Jul 2026 | 1,138 | Limit-up intraday (₩1,323) on control-change news | Edaily; Dealsite |
8 Jul 2026 | 996 | First close below ₩1,000 | Dealsite |
23 Jul 2026 | 760 | — | Dealsite; Bullstory |
18 Aug 2026 | 990 | — | Dealsite |
About 20 Aug 2026 | 1,003 | One session above ₩1,000 | Dealsite |
28 Aug 2026 | 943 | — | Dealsite |
17 Sep 2026 | 664 | — | MyDailyByte |
22 Sep 2026 | 678 | Market cap about KRW 24.6bn | Valueline |
29 Sep 2026 | 949 | +23.41% on EGM day | Digital Today |
12 Oct 2026 | 619 | −7.61%; market cap about KRW 23.2bn | StockHub |
Share Price & Returns
| Period | Return | Source |
|---|---|---|
1-year | About −63.5% to −66.6% (as of Aug–Sep 2026) | Investing.com |
52-week range | ₩550–₩2,550 (as of 12 Oct 2026); earlier displays show ₩674–₩2,775 | StockHub; Investing.com |
3-year / 5-year | Not publicly disclosed in reviewed sources | — |
Stock splits | Investing.com reports three past splits (details not publicly disclosed). A further 2:1 consolidation is scheduled for 16 Oct 2026. | Investing.com; Money Today |
Valuation Multiples
| Multiple | AinsFac CNS |
|---|---|
P/E | n/m (losses) |
EV/EBITDA | n/m (negative EBITDA likely; EBITDA not disclosed) |
EV/Sales | Not computable (net debt not disclosed). Price/Sales about 6.4x TTM. |
P/B | 0.35–0.37x |
Capital Markets
| Item | Status | Source |
|---|---|---|
Analyst consensus | None (0 reports) | StockHub |
Dividend history and policy | No dividends; yield 0.00% | StockHub |
Buyback authorisations | None; treasury shares 0.00% | Butler.works |
Credit ratings (Moody's / S&P / Fitch) | None (unrated) | — |
Action Details
| Action | Date | Effect |
|---|---|---|
2:1 share consolidation | 16 Oct 2026 (scheduled) | Par value ₩500 → ₩1,000 |
5:1 capital reduction (no consideration) | 29 Oct 2026 (scheduled) | Shares 37.51m → about 3.75m (combined with the consolidation). Share capital about KRW 18.8bn → about KRW 3.8bn. Theoretical price ×10. |
Third-party placement | 23 Dec 2026 | KRW 10bn; Acro stake to about 33.5% |
Authorised capital and debt-linked limits | Per EGM agenda | Authorised shares 5bn; CB and BW limits KRW 5tn each; EB limit KRW 5tn |
Analyst Conclusions
Management guidance and consensus
Management guidance: none publicly disclosed.
Consensus estimates: none (no coverage).
Bull case (grounded in disclosed data)
-
Recapitalised by a committed owner. The new controller paid KRW 33.96bn in cash for 12.75% and is contracted to inject KRW 10bn more by 23 Dec 2026. That roughly KRW 44bn of commitment is almost twice the current market cap and signals a far higher private valuation.
-
Asset backing. Book equity of KRW 65.6bn against about KRW 23bn of market value (P/B about 0.35x) leaves room for a re-rating if the investment portfolio is real and realisable.
-
Robotics optionality. HMR has differentiated technology (CES 2025 award, Health Canada approval), an IPO mandate and an ASEAN distributor. A successful HMR listing could surface value for the parent's stake.
Bear case (grounded in disclosed data)
-
Operations are shrinking toward irrelevance. TTM revenue is KRW 3.6bn, operating losses persist and H1 2026 losses rose 74%.
-
Listing risk is acute. The price was below ₩1,000 for most of Jul–Oct 2026 and market cap is near the KRW 20bn floor, which rises to KRW 30bn in January 2027. Korean evidence shows 83% of 2026 consolidations were followed by price declines.
-
Governance and dilution. The controller premium versus discounted placement, unusual trading concentration, two payment delays and a 50x increase in convertible capacity together raise a high risk that minority value is transferred elsewhere.
Key catalysts and monitorables (next 12 months)
-
Completion of the 16 Oct consolidation and 29 Oct capital reduction, and the post-relisting price relative to the ₩1,000 and market-cap thresholds.
-
Payment of the KRW 10bn placement on 23 Dec 2026.
-
Any formal administrative-issue designation and the subsequent 90-day / 45-day compliance window.
-
Disclosure of the new co-CEOs' business plan and any first investments in the new sectors.
-
Any CB, BW or EB issuance under the expanded limits.
-
The FY2026 business report (March 2027): revenue, impairments, auditor's opinion and any going-concern emphasis.
-
Progress on the HMR IPO filing and on FDA/MFDS approvals for XoMotion-R.
-
Beno Bio licensing or clinical milestones.
Analyst verdict
AinsFac CNS is best understood as a listed shell-in-transition, not an operating growth company.
How the business got here. Over a decade the entity has moved through several identities:
-
a Chinese-game publisher;
-
a bio holding company;
-
an interior-construction and exoskeleton group;
-
now a self-declared platform for semiconductor, battery, energy and recycling businesses.
Each identity arrived with a change of control or a rename rather than with organic operating success.
What the numbers show. Revenue has fallen from KRW 26.7bn in FY2021 to about KRW 3.6bn on a trailing basis. Operating losses have run for four years. Net losses repeatedly exceed operating losses, which suggests a balance sheet whose carrying values are at risk.
The bull and bear arguments. The strongest bull argument is arithmetic. Book equity of KRW 65.6bn and roughly KRW 44bn of fresh controller commitments sit against a market value near KRW 23bn. The new owner, whose fund is majority-backed by the similarly named 아인스팩, presumably intends to use the listing and its newly enlarged financing capacity to acquire or build businesses. However, the same features that create upside create risk:
-
authorised shares up tenfold, and convertible capacity raised to KRW 5tn;
-
a history of trading irregularities and minority-unfriendly pricing;
-
a regulatory regime that is now actively delisting penny stocks and sub-scale issuers.
Assessment. Shareholder outcomes over the next 12 months will depend almost entirely on capital-markets events: whether the share consolidation holds, whether the December placement is paid, and what the new management does with the expanded financing authority. Underlying fundamentals will matter far less. Until the company publishes a credible business plan with committed capital, and survives the 2027 market-cap test, the equity should be treated as a high-risk special situation. Its outcome distribution includes delisting, heavy dilution or a reverse-merger-style reinvention. The robotics and bio assets provide some real but unquantified option value, which current disclosure does not allow investors to price.
Overall rating (qualitative): Speculative / high risk. Insufficient disclosure for a fundamental valuation.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Background | Source |
|---|---|---|---|---|
Shin Dong-beom (신동범) | Co-CEO; inside director | From Sep 2026 | Not publicly disclosed in reviewed sources | Korean Wikipedia; Bloter (nominee) |
Kim Jeong-min (김정민) | Co-CEO; inside director | From Sep 2026 | Not publicly disclosed in reviewed sources | Korean Wikipedia; Bloter (nominee) |
Lee Gyo-in (이교인) | Independent director (nominee at the 29 Sep 2026 EGM) | From Sep 2026 (if elected) | — | Bloter |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Role | Period | Notes | Source |
|---|---|---|---|---|
Lee Tae-hyun (이태현) | CEO, Entermate | Around 2015 | Led the 2015 SPAC listing. Some data providers (Simply Wall St) still list him as CEO, which is out of date. | iNews24; Simply Wall St |
Jeong Jip-hun (정집훈) | CEO, Benoholdings / BENO TNR | About 2020 to Sep 2026 | Certified public accountant. Held 26.73% of Lamicus (2023). Sold 230,000 personal shares (0.61%) to Acro in Sep 2026. | Sidae Ilbo; Asia Economy; DART via Special Times |
Park Hyung-jun (박형준) | Chairman; controlled the company via Lamicus (73.27% of Lamicus) | 2023–2026 | Described as an M&A specialist. Spouse Ko Seong-hee was the largest holder of the prior controlling shareholder, J&J Investment. Exited in 2026 at roughly double his investment over about five years. | Sidae Ilbo; Chosun Biz via Daum |
Kim Sung-wook (김성욱) | CEO, Beno Bio | 2020 (current status not publicly disclosed) | — | Asia Economy (2020) |
Siamak Arzanpour | Co-founder and CEO, Human in Motion Robotics | Current as of 2023 | Simon Fraser University engineering professor | News Tomato; Asia Economy |
Park Jung-wook (Edward Park) | Co-founder, Human in Motion Robotics; co-CEO, HMR Asia | Current as of 2025 | Simon Fraser University professor; keynote speaker at the Korean Academy of Rehabilitation Medicine international conference (2025) | Asia Economy |
Cho Jun-young (조준영) | Co-CEO, HMR Asia | As of Dec 2023 | — | Asia Economy |
Governance Overview
| Item | Status |
|---|---|
Committee structure | Not publicly disclosed (KOSDAQ companies below KRW 2tn in assets are not required to have an audit committee) |
Major Shareholders
| Holder | Shares | Stake | Date | Source |
|---|---|---|---|---|
Acro New Technology Fund No.241 | 4,782,496 | 12.75% | 28 Sep 2026 | DART filing via Special Times |
— pro forma after the KRW 10bn placement (23 Dec 2026) | 16,519,585 (pre-consolidation basis) | About 33.5% | Scheduled | Money Today via Nate |
Acro Fund No.241's largest investor | 아인스팩 (AinsFac) | 50.95% of the fund | 2026 | Dealsite (28 Aug 2026) |
Lamicus and related parties (prior controller) | Sold 4,552,496 (Lamicus) and 230,000 (Jeong Jip-hun) | 12.14% and 0.61% before the sale | Before 28 Sep 2026 | DART via Special Times |
Chris F&C (크리스에프앤씨) and 1 other | — | 8.71% (as reported in Korean Wikipedia's 2025-basis infobox) | — | Korean Wikipedia |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Competitor | Country | Positioning vs. XoMotion |
|---|---|---|
Wandercraft (Atalante) | France | Most direct technological peer: self-balancing, hands-free exoskeleton for rehabilitation |
Ekso Bionics | US | Established rehab exoskeleton supplier; crutch-assisted designs |
Lifeward (formerly ReWalk Robotics) | Israel/US | Personal and rehab exoskeletons; US reimbursement pathway |
Cyberdyne (HAL) | Japan | Bio-signal-driven exoskeleton; strong presence in Japan and APAC |
Angel Robotics | Korea (KOSDAQ-listed) | Domestic wearable-robot leader; direct Korean competitor for hospital channels |
Hyundai Motor Group robotics (X-ble line) | Korea | Large-group wearable-robot programme |
Fourier Intelligence | China | Rehabilitation robotics platform with APAC reach |
Peer Comparison FY2025
| Metric | AinsFac CNS | Wandercraft |
|---|---|---|
Latest revenue | KRW 4.77bn (FY2025) | Not publicly disclosed (private) |
Revenue growth | −81.1% (FY2025) | — |
Operating margin | −112.3% (FY2025) | — |
“—” = not publicly disclosed.
Recent Developments
Status caveat.



